Fjarde Ap Fonden Ionis Pharmaceuticals Inc Transaction History

Fjarde Ap Fonden

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 12, 2021	SELL	$34.54 - $47.25 $1.99 Million - $2.72 Million	-57,500 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$42.51 - $63.78 $144,534 - $216,852	3,400 Added 6.28%	57,500 $2.59 Million
Q4 2020 Feb 12, 2021	BUY	$45.3 - $60.27 $49,830 - $66,297	1,100 Added 2.08%	54,100 $3.06 Million
Q3 2020 Nov 13, 2020	BUY	$47.45 - $62.95 $265,720 - $352,520	5,600 Added 11.81%	53,000 $2.52 Million
Q2 2020 Aug 13, 2020	SELL	$46.85 - $61.05 $89,015 - $115,995	-1,900 Reduced 3.85%	47,400 $2.8 Million
Q1 2020 May 11, 2020	BUY	$41.6 - $63.4 $20,800 - $31,700	500 Added 1.02%	49,300 $2.33 Million
Q4 2019 Feb 10, 2020	BUY	$53.85 - $65.27 $910,065 - $1.1 Million	16,900 Added 52.98%	48,800 $2.95 Million
Q3 2019 Oct 31, 2019	SELL	$59.06 - $72.15 $29,530 - $36,075	-500 Reduced 1.54%	31,900 $1.91 Million
Q2 2019 Jul 17, 2019	BUY	$62.09 - $86.14 $2.01 Million - $2.79 Million	32,400 New	32,400 $2.08 Million

403

136M

862K

582K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.35B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

Stay updated on Fjarde Ap Fonden with notifications on news.